Mutation of serine 102 of HMGA1, a CK2 phosphorylation site, was found to restore the efficacy of gefitinib through the reactivation of the downstream signaling pathway of EGFR in drug-resistant NSCLC cells [25]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.